Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes
Sponsor: Faculty of Medicine, Sousse
Summary
The primary objective of this clinical trial is to evaluate the efficacy and safety of a topical Urtica dioica cataplasm in managing knee pain and functional limitations in athletic children diagnosed with Osgood-Schlatter Disease. Efficacy will be assessed through changes in knee pain using the Visual Analog Scale (VAS) and functional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Three groups will be tested: * UDC Group: topical application of Urtica dioica cataplasm * Standard Care Group: oral vitamin D supplementation and physical rest * Placebo Group: topical application of a placebo cataplasm using Beta vulgaris subsp. cicla
Official title: Evaluation of Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes: A Study Protocol for Randomized, Double-blind, Placebo Controlled Clinical Trial
Key Details
Gender
MALE
Age Range
7 Years - 15 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-09-01
Completion Date
2026-09-30
Last Updated
2025-08-01
Healthy Volunteers
No
Conditions
Interventions
Urtica dioica cataplasm
Participants will receive a warm Urtica dioica cataplasm applied topically on the affected knee, once daily for 60 minutes, three times per week (on alternate days) over a 6-week period.
Placebo
Participants will receive a placebo cataplasm, matched in texture, color, and odor to the active treatment. The placebo is inert and safe for pediatric topical use.
Vitamin D
Participants will receive oral vitamin D.
Resting conditions
Reduction in physical activity based on orthopedic advice.